Pimavanserin

Common card · No. 471930

Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. It is taken by mouth. Side effects of pimavanserin include peripheral edema and confusion. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist, but rather is a selective antagonist or inverse agonist of the serotonin 5-HT2A receptor and to a lesser extent of the serotonin 5-HT2C receptor. Pimavanserin was first approved for medical use in 2016. It was approved as a generic medication in 2024.

Read on Wikipedia · Image Vaccinationist, Public domain